



February 19th, 2014
Press Release



Innovative Targeting Solutions Inc. Extends Research Collaboration with Amgen

Burnaby, BC – February 19th, 2014- Innovative Targeting Solutions Inc. (ITS), the developer of the next generation protein engineering technology (HuTARG™), today announced the extension of its research collaboration with Amgen Inc. (Thousand Oaks, CA) that allows Amgen to internalize ITS' HuTARG™ technology. Under the terms of the agreement, ITS is entitled to specific license payments and development milestones.

About Innovative Targeting Solutions Inc.

Founded in 2008, Innovative Targeting Solutions Inc. is a privately-held company that has developed a next generation platform for the generation of fully human antibody therapeutics using its proprietary HuTARG™ technology. The HuTARG™ technology is a fully mammalian technology that generates antibody diversity *in vitro* via RAG1/RAG2 mediated V(D)J recombination. For more information, visit www.innovativetargeting.com

Contact:
Paul Kang
Tel: 604|433-6779
Email: pkang@innovativetargeting.com

